赛托生物(300583) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥241,425,650.02, representing a year-on-year increase of 21.70%[4] - The net profit attributable to shareholders was -¥16,543,142.49, a significant decline of 1,199.98% compared to the same period last year[4] - The basic earnings per share for Q3 2025 was -¥0.08, reflecting a decrease of 900.00% year-on-year[4] - The total profit for the year-to-date was -¥75,201,207.54, a decline of 462.69% compared to the same period last year[9] - Net profit for the period was a loss of ¥79,128,524.62, compared to a profit of ¥13,200,659.89 in the previous period, indicating a significant decline[19] - Operating profit turned negative at -¥74,138,162.11, down from a positive ¥21,181,969.70 in the prior year[19] - Basic and diluted earnings per share were both -¥0.36, compared to ¥0.08 in the previous period[20] Cash Flow - The cash flow from operating activities for the year-to-date was ¥77,809,222.82, down 53.96% from the previous year[4] - The net cash flow from operating activities was $77.81 million, a decrease of 54% compared to $169.01 million in the previous period[22] - Cash inflow from operating activities totaled ¥553,336,844.67, down from ¥607,886,012.30, a decrease of approximately 8.9% year-over-year[21] - Cash outflows from operating activities totaled $475.53 million, compared to $438.87 million in the prior period[22] - The net cash flow from investing activities was -$27.43 million, an improvement from -$61.30 million year-over-year[22] - Cash inflows from investment activities totaled $10.52 million, significantly higher than $2.36 million in the prior period[22] Assets and Liabilities - Total assets at the end of Q3 2025 were ¥2,866,079,082.42, a decrease of 5.28% from the end of the previous year[4] - Total current assets decreased from 1,284,916,162.65 CNY to 1,189,810,971.39 CNY, a decline of approximately 7.41%[14] - Total assets decreased from 3,025,806,782.53 CNY to 2,866,079,082.42 CNY, a decline of approximately 5.26%[14] - Total non-current assets decreased from 1,740,890,619.88 CNY to 1,676,268,111.03 CNY, a decline of approximately 3.71%[14] - The total liabilities decreased to ¥1,064,836,700.02 from ¥1,141,641,832.99, a reduction of approximately 6.7%[19] - Total equity attributable to shareholders decreased to ¥1,766,097,218.21 from ¥1,839,121,540.57, a decline of about 4.0%[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,737[11] - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 22.82% of shares, totaling 43,297,382 shares, with 7,440,000 shares pledged[11] - The second-largest shareholder, Mi Chaojie, holds 20.62% of shares, totaling 39,116,800 shares[11] Investment and Expenses - The company experienced a 50.40% decrease in investment income, totaling ¥5,391,355.27 for the year-to-date[8] - Research and development expenses were ¥32,249,551.03, down from ¥41,391,541.00, reflecting a reduction of about 22.1%[19] - Cash paid to employees was $83.66 million, down from $107.49 million year-over-year[22] - Cash paid for taxes was $23.87 million, a decrease from $40.83 million in the previous period[22] - Cash paid for the acquisition of fixed assets was $34.96 million, down from $63.66 million year-over-year[22] Credit and Impairment - The company reported a 514.07% increase in credit impairment losses, amounting to -¥9,637,137.21 for the year-to-date[8] - The company reported a credit impairment loss of -¥9,637,137.21, compared to a gain of ¥2,327,445.50 in the previous period[19]